Indian Drugmaker Aims to Launch Generic Obesity Drug

Dr Reddy's plans to offer Wegovy alternative at 60% discount if approved

Published on Feb. 18, 2026

Indian pharmaceutical company Dr Reddy's Laboratories is planning to launch a generic version of Novo Nordisk's popular weight loss drug Wegovy, pending regulatory approval. The company aims to offer the generic drug at a 60% discount to the branded version.

Why it matters

Wegovy has become a blockbuster drug for treating obesity, but its high cost has limited access for many patients. A more affordable generic option could significantly expand access to this type of obesity treatment.

The details

Dr Reddy's said it plans to launch the generic version of Wegovy, semaglutide, subject to receiving the necessary regulatory approvals. The company aims to offer the generic drug at a 60% discount to the branded Wegovy product.

  • Dr Reddy's announced its plans on February 17, 2026.

The players

Dr Reddy's Laboratories

An Indian pharmaceutical company that develops and manufactures generic drugs.

Novo Nordisk

A Danish multinational pharmaceutical company that developed and markets the branded Wegovy weight loss drug.

Wegovy

A prescription medication used for chronic weight management in adults with obesity or overweight with at least one weight-related condition.

Got photos? Submit your photos here. ›

What’s next

Dr Reddy's will need to receive regulatory approval from the appropriate authorities before it can launch the generic version of Wegovy.

The takeaway

The potential launch of a more affordable generic version of Wegovy could significantly improve access to this effective obesity treatment, helping to address the high cost that has limited its use so far.